MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
81,398
96,430
33,864
18,016
Cost of Revenue
33,206
41,057
-
-
Gross Profit
48,192
55,373
-
-
Operating Expenses
Research Development
23,989
55,409
49,475
81,686
Selling General and Administrative
112,745
133,312
63,325
53,538
Total Operating Expenses
135,251
182,893
112,800
135,224
Operating Income or Loss
-87,059
-127,520
-78,936
-117,208
Interest Expense
36,311
43,179
7,624
1,228
Total Other Income/Expenses Net
-197,861
12,777
27,489
-753
Income Before Tax
-320,214
-157,192
-58,916
-117,961
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-320,214
-157,192
-58,916
-117,961
Net Income
-320,214
-157,192
-58,916
-117,961
Net Income available to common shareholders
-320,214
-157,192
-78,175
-117,961
Reported EPS
Basic
-
-17.12
-109.30
-58.50
Diluted
-
-17.12
-109.30
-58.50
Weighted average shares outstanding
Basic
-
9,182
715
2,013
Diluted
-
9,182
715
2,013
EBITDA
-
-97,112
-50,841
-117,208